한국어
English
日本語
中文(简体)
Kisqali Tablet 200 mg (Ribociclib Succinate)
254.4mg
Tablet · Prescription medication
Korea Novartis Co., Ltd.
Ribociclib succinate is an antineoplastic drug ingredient used for the treatment of hormone receptor-positive breast cancer.
MFDS ingredient code M270078
Ribociclib succinate is an anticancer agent that selectively inhibits the enzymes CDK4 and CDK6, which are involved in cell cycle regulation. It is primarily used in the treatment of hormone receptor-positive breast cancer patients and is included in medications to suppress the proliferation of cancer cells.
Ribociclib succinate stops the process of cell division by blocking the activity of the enzymes CDK4 and CDK6 within cancer cells. As a result, cancer cells can no longer proliferate, and their growth rate is slowed down.
Approved uses differ by product. Check each product's information for its actual use.
Ribociclib succinate is one of the CDK4/6 inhibitors, and it is distinguished from similar acting agents such as palbociclib or abemaciclib. Each ingredient differs in pharmacokinetics and side effect profiles, making selection dependent on the patient's condition.
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, dosage and approved uses can differ by strength, dosage form and combined ingredients. Check each product's information before taking it.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
Product approval information is based on drug information provided by the Ministry of Food and Drug Safety.
Ingredient and class descriptions are not part of MFDS data and were written separately by Cashdoc.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.